281 related articles for article (PubMed ID: 22437921)
1. Appearance of hepatocellular adenomas on gadoxetic acid-enhanced MRI.
Denecke T; Steffen IG; Agarwal S; Seehofer D; Kröncke T; Hänninen EL; Kramme IB; Neuhaus P; Saini S; Hamm B; Grieser C
Eur Radiol; 2012 Aug; 22(8):1769-75. PubMed ID: 22437921
[TBL] [Abstract][Full Text] [Related]
2. Gadoxetic acid enhanced MRI for differentiation of FNH and HCA: a single centre experience.
Grieser C; Steffen IG; Kramme IB; Bläker H; Kilic E; Perez Fernandez CM; Seehofer D; Schott E; Hamm B; Denecke T
Eur Radiol; 2014 Jun; 24(6):1339-48. PubMed ID: 24658870
[TBL] [Abstract][Full Text] [Related]
3. MRI for characterization of benign hepatocellular tumors on hepatobiliary phase: the added value of in-phase imaging and lesion-to-liver visual signal intensity ratio.
Lebert P; Adens-Fauquembergue M; Azahaf M; Gnemmi V; Behal H; Luciani A; Ernst O
Eur Radiol; 2019 Nov; 29(11):5742-5751. PubMed ID: 30993437
[TBL] [Abstract][Full Text] [Related]
4. Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping.
Reizine E; Ronot M; Pigneur F; Purcell Y; Mulé S; Dioguardi Burgio M; Calderaro J; Amaddeo G; Laurent A; Vilgrain V; Luciani A
Eur Radiol; 2019 Jul; 29(7):3791-3801. PubMed ID: 30937584
[TBL] [Abstract][Full Text] [Related]
5. Focal Nodular Hyperplasia and Hepatocellular Adenoma: Accuracy of Gadoxetic Acid-enhanced MR Imaging--A Systematic Review.
McInnes MD; Hibbert RM; Inácio JR; Schieda N
Radiology; 2015 Nov; 277(2):413-23. PubMed ID: 26020440
[TBL] [Abstract][Full Text] [Related]
6. Histopathologically confirmed focal nodular hyperplasia of the liver: gadoxetic acid-enhanced MRI characteristics.
Grieser C; Steffen IG; Seehofer D; Kramme IB; Uktolseya R; Scheurig-Muenkler C; Hamm B; Denecke T
Magn Reson Imaging; 2013 Jun; 31(5):755-60. PubMed ID: 23219272
[TBL] [Abstract][Full Text] [Related]
7. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
Lee MH; Kim SH; Park MJ; Park CK; Rhim H
AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis.
Grazioli L; Bondioni MP; Haradome H; Motosugi U; Tinti R; Frittoli B; Gambarini S; Donato F; Colagrande S
Radiology; 2012 Feb; 262(2):520-9. PubMed ID: 22282184
[TBL] [Abstract][Full Text] [Related]
9. HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI.
Auer TA; Walter-Rittel T; Geisel D; Schöning W; Schmelzle M; Müller T; Sinn B; Denecke T; Hamm B; Fehrenbach U
BMC Med Imaging; 2021 Feb; 21(1):28. PubMed ID: 33588783
[TBL] [Abstract][Full Text] [Related]
10. Hepatospecific MR contrast agent uptake on hepatobiliary phase can be used as a biomarker of marked β-catenin activation in hepatocellular adenoma.
Reizine E; Ronot M; Ghosn M; Calderaro J; Frulio N; Bioulac-Sage P; Trillaud H; Vilgrain V; Paradis V; Luciani A
Eur Radiol; 2021 May; 31(5):3417-3426. PubMed ID: 33146794
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular adenomas: is there additional value in using Gd-EOB-enhanced MRI for subtype differentiation?
Auer TA; Fehrenbach U; Grieser C; Penzkofer T; Geisel D; Schmelzle M; Müller T; Bläker H; Seehofer D; Denecke T
Eur Radiol; 2020 Jun; 30(6):3497-3506. PubMed ID: 32086574
[TBL] [Abstract][Full Text] [Related]
12. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW
AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994
[TBL] [Abstract][Full Text] [Related]
13. Gadoxetic acid-enhanced MRI findings of early hepatocellular carcinoma as defined by new histologic criteria.
Rhee H; Kim MJ; Park YN; Choi JS; Kim KS
J Magn Reson Imaging; 2012 Feb; 35(2):393-8. PubMed ID: 21990116
[TBL] [Abstract][Full Text] [Related]
14. MRI features of inflammatory hepatocellular adenomas on hepatocyte phase imaging with liver-specific contrast agents.
Thomeer MG; Willemssen FE; Biermann KK; El Addouli H; de Man RA; Ijzermans JN; Dwarkasing RS
J Magn Reson Imaging; 2014 May; 39(5):1259-64. PubMed ID: 23897798
[TBL] [Abstract][Full Text] [Related]
15. Hepatic Adenoma Subtypes on Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI: Systematic Review and Meta-Analysis.
Kim TH; Woo S; Ebrahimzadeh S; McInnes MDF; Gerst SR; Do RK
AJR Am J Roentgenol; 2023 Jan; 220(1):28-38. PubMed ID: 35920706
[No Abstract] [Full Text] [Related]
16. Enhancement pattern of hepatocellular adenoma (HCA) on MR imaging performed with Gd-EOB-DTPA versus other Gd-based contrast agents (GBCAs): An intraindividual comparison.
Cannella R; Brancatelli G; Rangaswamy B; Minervini MI; Borhani AA; Furlan A
Eur J Radiol; 2019 Oct; 119():108633. PubMed ID: 31437747
[TBL] [Abstract][Full Text] [Related]
17. The target sign in colorectal liver metastases: an atypical Gd-EOB-DTPA "uptake" on the hepatobiliary phase of MR imaging.
Granata V; Catalano O; Fusco R; Tatangelo F; Rega D; Nasti G; Avallone A; Piccirillo M; Izzo F; Petrillo A
Abdom Imaging; 2015 Oct; 40(7):2364-71. PubMed ID: 26105523
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of MRI features of hepatocyte nuclear factor 1α-inactivated hepatocellular adenoma].
Pan H; Chen XF; Han J; Ji Y; Zeng MS; Wang ML
Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1192-1197. PubMed ID: 38238954
[No Abstract] [Full Text] [Related]
19. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory hepatic adenomas: Characterization with hepatobiliary MRI contrast agents.
Glockner JF; Lee CU; Mounajjed T
Magn Reson Imaging; 2018 Apr; 47():103-110. PubMed ID: 29221964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
